BackPropanc Biopharma Overview

Propanc Biopharma Net Tangible Assets

Track Propanc Biopharma's net tangible assets ($9.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$9.83M
45.68% YoYΔ $-8.26M vs prior year quarter

Peer trimmed avg / median

Loading

Propanc Biopharma Net Tangible Assets History

Loading

Propanc Biopharma vs. peers: Net Tangible Assets Comparison

Loading

Propanc Biopharma Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Propanc Biopharma (PPCB) FAQ

As of the most recent data (March 2026), PPCB shows a net tangible assets of $9.8M. That compares with $18M in the prior-year period — down 45.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PPCB's net tangible assets is now $9.8M (was $18M) — a 45.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Propanc Biopharma is outperforming or lagging.

Tracking PPCB's net tangible assets over time shows whether Propanc Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $9.8M That compares with $18M in the prior-year period — down 45.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Propanc Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $9.8M) with ownership activity and broader fundamentals.

Propanc Biopharma's net tangible assets is $9.8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.